One-carbon Therapeutics

One-carbon therapeutics AB is a privately held company incorporated in Sweden. They focusses on late-stage pre-clinical development of its primary clinical drug candidate targeting MTHFD2 to prepare for phase I trials expected in 2023.

One-carbon Therapeutics are taking their previous success of discovering the PARP inhibitor concept for the treatment of BRCA mutated cancer to a new level; exploiting cancer-specific metabolism to target the DDR, and cause cancer-specific DNA damage at replication forks.

One-carbon therapeutics has secured seed funding and is already now interested in establishing relationship with VCs potentially interested in syndication in an A series investment round.